Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparative adjuvant study of Env-C DNA and gp145 protein HIV vaccines in Kenya
PACTR202009737295685Phase 1Not yet recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Nov 2020
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1 trial of gp145 C.6980 in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Systemic reactogenicity and Local reactogenicity. Planned start Nov 2020; status: not yet recruiting.
02
Drugs
gp145 C.6980
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202009737295685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202009737295685.